Investment Thesis
Pulse Biosciences is a pre-commercial or very early-stage medical device company with only $350K in revenue against $76.9M in operating losses, indicating it has not yet achieved meaningful commercialization. While the company maintains a strong cash position of $80.7M with zero debt and excellent liquidity, the accelerating losses (down 35.8% YoY), massive cash burn of $54.1M annually, and absence of revenue traction suggest execution risk and a runway of approximately 18-24 months at current burn rate. Without demonstrated product-market fit or credible near-term commercialization pathway, the company presents a highly speculative, high-risk fundamental profile.
Strengths
- Strong cash position of $80.7M with no debt, providing 18-24 month runway
- Excellent liquidity metrics (current ratio 10.53x, quick ratio 10.51x)
- Operates in medical device sector with potential for high-margin products at scale
- Minimal liabilities ($13.9M) relative to equity base
Risks
- Pre-commercial or extremely early-stage revenue ($350K) with no evidence of business traction
- Massive operating losses ($76.9M) accelerating YoY (-35.8% net income deterioration)
- Negative operating cash flow of $54.1M annually indicates unsustainable burn rate
- No visibility to near-term profitability or clear path to revenue growth
- High execution risk typical of clinical-stage or development-stage medtech companies
- Cash depletion risk if commercialization is delayed or unsuccessful
Key Metrics to Watch
- Quarterly revenue growth and path to meaningful commercialization
- Operating cash burn rate and cash runway remaining
- Clinical trial progress, regulatory approvals, and product launch timelines
- Gross margin achievement once products reach meaningful scale
- Insider buying/selling patterns as indicator of management confidence
Financial Metrics
Revenue
350.0K
Net Income
-72.8M
EPS (Diluted)
$-1.50
Free Cash Flow
-54.4M
Total Assets
94.5M
Cash
80.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-21,982.6%
Net Margin
-20,794.6%
ROE
-90.2%
ROA
-77.0%
FCF Margin
-15,553.4%
Balance Sheet & Liquidity
Current Ratio
10.53x
Quick Ratio
10.51x
Debt/Equity
0.00x
Debt/Assets
14.7%
Interest Coverage
-121.93x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T09:39:23.237695 |
Data as of: 2025-12-31 |
Powered by Claude AI